Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2011-04-05
2011-04-05
Paras, Jr., Peter (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S008000, C800S018000
Reexamination Certificate
active
07919671
ABSTRACT:
A method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the activity or the level of prostatic acid phosphatase. The compound may be used for treating disorders related to unbalanced phosphatidylinositol phosphate cascade or signaling pathway. Diagnostic methods and methods for treating the disorders with therapeutic compounds or by gene therapy are also disclosed.
REFERENCES:
patent: 0043548 (2000-07-01), None
patent: 02063013 (2002-08-01), None
patent: 2004096153 (2004-11-01), None
Kaneko et al., 1995, Internal Med., vol. 34 pp. 886-891.
2004, Barthold S., Genetica, vol. 122, pp. 75-88.
2009, Doetschman T., Methods Mol. Biol., vol. 530, pp. 423-433.
2004, Crusio et al., Biol. Psychiatry, vol. 56, pp. 381-385.
Moreadith, 1997, J. Mol. Med., vol. 75 pp. 208-216.
Prelle, 1999, Cell Tissues Organs, vol. 165, pp. 220-236.
Smith, Journal of Biotechnology, vol. 99, pp. 1-22, 2002.
Denning et al. Reproduction, vol. 126, pp. 1-11, 2003.
Baker et al., 2000, Int. J. Human-Computer Studies, vol. 52 pp. 1-16.
“Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase”, T. Igawa et al., The Prostate, Apr. 18, 2003, vol. 55, pp. 247-258.
“Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic cancer,” S. Wang et al., Cancer Cell, Sep. 2003, vol. 4, pp. 209-221.
“Prostatic acid phosphatase (PAP) is (P1(3)P-phosphatase and its inactivation leads to change of cell polarity and invasive prostate cancer,” P. T. Vihko et al., Apr. 19, 2005; Proceedings of the AACR, 9thannual meeting, Apr. 16-20, 2005.
“Decreased Expression of Cellular Prostatic Acid Phosphatase Increases Tumorigenicity of Human Prostate Cancer Cells,” Lin et al., The Journal of Urology, Nov. 2001, vol. 166, pp. 1943-1950.
“Genetically defined mouse models that mimic natural aspects of human prostate cancer development,” Roy-Burman et al., Endocrine-Related Cancer, Jun. 2004, vol. 11, No. 2, pp. 225-254.
Hakalahti et al., “Evaluation of PAP and PSA Gene Expression in Prostatic Hyperplasia and Prostatic Carcinoma Using Northern-Blot Analyses, in Situ Hybridization and Immunohistochemical Stainings with Monoclonal and Bispecific Antibodies”, International Journal of Cancer, vol. 55, No. 4, 1993, pp. 590-597, XP002519632.
Chu et al., “PSA and Acid Phosphate in the Diagnosis of Prostate Cancer”, Journal of Clinical Ligand Assay, vol. 21, No. 1, Apr. 1998, pp. 24-34, XP009113612.
European Search Report dated Mar. 19, 2009 from corresponding EP Application No. 05813227.5.
Chempath Oy
Montanari David
Paras, Jr. Peter
Young & Thompson
LandOfFree
Method for testing a compound for a therapeutic effect and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for testing a compound for a therapeutic effect and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for testing a compound for a therapeutic effect and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731663